QQ客服 官方微博 反馈留言

浏览/检索结果: 共4条，第1-4条 帮助 已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Ribociclib (LEE011) suppresses cell proliferation and induces apoptosis of MDA-MB-231 by inhibiting CDK4/6-cyclin D-Rb-E2F pathway 期刊论文 ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY, 2019, 卷号: 47, 期号: 1 作者:  Li, Tianqi;  Xiong, Yudi;  Wang, Qingqing;  Chen, Fengxia;  Zeng, Yangyang 收藏  |  浏览/下载：22/0  |  提交时间：2019/12/05 Triple-negative breast cancer  ribociclib (LEE011)  proliferation  cell cycle  apoptosis   Phase III, randomized, double-blind, placebo-controlled study of ribociclib (LEE011) in combination with either tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with HR+, HER2-advanced breast cancer (aBC): MONALEESA-7 期刊论文 Journal of Clinical Oncology, 2015, 卷号: 33 作者:  Tripathy D., Bardia A., Hurvitz S.A., Harbeck N., Colleoni M., Franke F.A., Chow L.W.C., Im S.-A., Shao Z., Keyserlingk J.R., Soler L.M., Horan M., Dhuria S.V., Hughes G., Lu Y.-S. 收藏  |  浏览/下载：12/0  |  提交时间：2019/12/19 MONALEESA-7: a phase III, randomized, double-blind, placebo-controlled study of ribociclib (LEE011) combined with standard first-line endocrine therapy (ET) for the treatment of premenopausal women with HR+, HER2-advanced breast cancer (aBC) 会议论文 作者:  Im, S. -A.;  Chow, L.;  Shao, Z.;  Tripathy, D.;  Bardia, A. 收藏  |  浏览/下载：6/0  |  提交时间：2019/12/19 Phase III, randomized, double-blind, placebo-controlled study of ribociclib (LEE011) in combination with either tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with HR+, HER2-advanced breast cancer (aBC): MONALEESA-7. 会议论文 作者:  Tripathy, Debu;  Bardia, Aditya;  Hurvitz, Sara A.;  Harbeck, Nadia;  Colleoni, Marco 收藏  |  浏览/下载：7/0  |  提交时间：2019/12/19